Systemic lupus erythematosus is associated with an increased risk for pulmonary manifestations, including ILD and pulmonary hypertension.

To assess how a patient with pulmonary arterial hypertension (PAH) is faring on therapy, look at the right heart, said Anjali ...

The Pulmonary Hypertension Association has launched a new certificate program for advanced practice providers and allied health professionals. The Pulmonary Hypertension Certificate program is ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

Exclusive e-cigarette use is significantly associated with new cases of chronic obstructive pulmonary disease.

A new study published in The New England Journal of Medicine showed that for high-risk patients with pulmonary arterial ...

E-cigarette use is linked to increased risk of COPD and possibly hypertension, though less harmful than traditional smoking, ...

The Pulmonary Hypertension Association will join more than 80 organizations globally on Monday, May 5, to recognize World Pulmonary Hypertension Day. "Early diagnosis leads to better outcomes," says ...

The Gateshead pharmaceutical firm has received an initial payment of $665,000 as part of the exclusive licence agreement ...

Commercial stage pharmaceutical firm Shield Therapeutics, which has a base in Gateshead, has entered into an exclusive licence agreement to commercialise its oral iron therapy drug in Japan.

Mizuho initiated coverage of Tectonic Therapeutic (TECX) with an Outperform rating and $51 price target The company’s lead asset, TX45, is a ...

Tenax Therapeutics progresses levosimendan for PH-HFpEF with Phase 3 trials, aiming for a first-of-its-kind therapy. Click ...